s6y

Allergan Funding SCS

CIK
1620554
Industry
Pharmaceutical Preparations
Formerly
Actavis Funding SCS

Prospectus 15

  1. 424B2 Prospectus filed pursuant to Rule 424(b)(2)
  2. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  3. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  4. S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
  5. 424B2 Prospectus filed pursuant to Rule 424(b)(2)
  6. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  7. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  8. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  9. 424B2 Prospectus filed pursuant to Rule 424(b)(2)
  10. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses

All 15 prospectus filings

Other 16

  1. 15-15D Notice of suspension of duty to file reports pursuant to Section 13 and 15(d) of the Act
  2. 15-15D Notice of suspension of duty to file reports pursuant to Section 13 and 15(d) of the Act
  3. 15-15D Notice of suspension of duty to file reports pursuant to Section 13 and 15(d) of the Act
  4. 15-12B Notice of termination of registration of a class of securities under Section 12(b)
  5. EFFECT Notice of Effectiveness
  6. POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing
  7. POSASR Post-effective Amendment to an automatic shelf registration statement on Form S-3ASR or Form F-3ASR
  8. 25 Notification filed by issuer to voluntarily withdraw a class of securities from listing and registration on a national securities exchange
  9. 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
  10. CERT Certification by an exchange approving securities for listing

All 16 other filings